MG
PALI icon

Michael Gelband’s Palisade Bio PALI Stock Holding History

Michael Gelband’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.3K Buy
24,561
+11,436
+87% +$22.5K ﹤0.01% 1485
2026
Q1 		$23K Buy
+13,125
New +$23.9K ﹤0.01% 1471

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Michael Gelband's PALI Position: Q2 2026 in Review

Michael Gelband increased its Palisade Bio (PALI) stake by 87% in Q2 2026, buying an estimated $22.5K and bringing the position to 24,561 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

Michael Gelband first reported a position in PALI in Q1 2026 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Michael Gelband held 24,561 shares of Palisade Bio worth $51.3K as of Q2 2026.
  • Michael Gelband bought 11,436 Palisade Bio shares in Q2 2026, an estimated $22.5K.
  • Palisade Bio made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1485 holding.
  • Michael Gelband first reported a position in Palisade Bio in Q1 2026 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.